{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T10:53:34Z","timestamp":1782816814248,"version":"3.54.5"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T00:00:00Z","timestamp":1698969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T00:00:00Z","timestamp":1698969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiol med"],"DOI":"10.1007\/s11547-023-01743-1","type":"journal-article","created":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T09:02:59Z","timestamp":1699002179000},"page":"315-327","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Optimising of axillary therapy in breast cancer: lessons from the past to plan for a better future"],"prefix":"10.1007","volume":"129","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4023-1869","authenticated-orcid":false,"given":"Orit","family":"Kaidar-Person","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trine","family":"Tramm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Kuehn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oreste","family":"Gentilini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleix","family":"Prat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Montay-Gruel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Icro","family":"Meattini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Poortmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,3]]},"reference":[{"issue":"3","key":"1743_CR1","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1200\/JCO.2009.26.8292","volume":"28","author":"B Fisher","year":"2010","unstructured":"Fisher B, Anderson SJ (2010) The breast cancer alternative hypothesis: is there evidence to justify replacing it? J clin oncol off j Am Soc Clin Oncol 28(3):366\u2013374. https:\/\/doi.org\/10.1200\/JCO.2009.26.8292","journal-title":"J clin oncol off j Am Soc Clin Oncol"},{"issue":"3","key":"1743_CR2","doi-asserted-by":"publisher","first-page":"308","DOI":"10.21037\/gs.2017.09.07","volume":"7","author":"MD Freeman","year":"2018","unstructured":"Freeman MD, Gopman JM, Salzberg CA (2018) The evolution of mastectomy surgical technique: from mutilation to medicine. Gland Surg 7(3):308\u2013315. https:\/\/doi.org\/10.21037\/gs.2017.09.07","journal-title":"Gland Surg"},{"issue":"1","key":"1743_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00000658-190707000-00001","volume":"46","author":"WS Halsted","year":"1907","unstructured":"Halsted WS (1907) The results of radical operations for the cure of carcinoma of the breast. Ann Surg 46(1):1\u201319. https:\/\/doi.org\/10.1097\/00000658-190707000-00001","journal-title":"Ann Surg"},{"issue":"1","key":"1743_CR4","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1002\/1097-0142(19810101)47:1<170::aid-cncr2820470128>3.0.co;2-c","volume":"47","author":"U Veronesi","year":"1981","unstructured":"Veronesi U, Valagussa P (1981) Inefficacy of internal mammary nodes dissection in breast cancer surgery. Cancer 47(1):170\u2013175. https:\/\/doi.org\/10.1002\/1097-0142(19810101)47:1%3c170::aid-cncr2820470128%3e3.0.co;2-c","journal-title":"Cancer"},{"issue":"22","key":"1743_CR5","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1056\/nejm199511303332202","volume":"333","author":"Effects of Radiotherapy and Surgery in Early Breast Cancer","year":"1995","unstructured":"Effects of Radiotherapy and Surgery in Early Breast Cancer (1995) An overview of the randomized trials. New Engl J Med 333(22):1444\u20131456. https:\/\/doi.org\/10.1056\/nejm199511303332202","journal-title":"New Engl J Med"},{"key":"1743_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102085","volume":"61","author":"O Kaidar-Person","year":"2023","unstructured":"Kaidar-Person O, Pfob A, Gentilini OD, Borisch B, Bosch A, Cardoso MJ, Curigliano G, De Boniface J, Denkert C, Hauser N, Heil J, Knauer M, Kuhn T, Lee HB, Loibl S, Mannhart M, Meattini I, Montagna G, Pinker K, Poulakaki F, Rubio IT, Sager P, Steyerova P, Tausch C, Tramm T, Vrancken Peeters MJ, Wyld L, Yu JH, Weber WP, Poortmans P, Dubsky P (2023) The lucerne toolbox 2 to optimise axillary management for early breast cancer: a multidisciplinary expert consensus. EClinicalMedicine 61:102085. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102085","journal-title":"EClinicalMedicine"},{"issue":"16","key":"1743_CR7","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1056\/NEJMoa020989","volume":"347","author":"U Veronesi","year":"2002","unstructured":"Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, Aguilar M, Marubini E (2002) Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 347(16):1227\u20131232","journal-title":"N Engl J Med"},{"issue":"6","key":"1743_CR8","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/0277-5379(90)90114-9","volume":"26","author":"U Veronesi","year":"1990","unstructured":"Veronesi U, Volterrani F, Luini A, Saccozzi R, Del Vecchio M, Zucali R, Galimberti V, Rasponi A, Di Re E, Squicciarini P et al (1990) Quadrantectomy versus lumpectomy for small size breast cancer. Eur J Cancer 26(6):671\u2013673","journal-title":"Eur J Cancer"},{"issue":"16","key":"1743_CR9","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1056\/NEJMoa022152","volume":"347","author":"B Fisher","year":"2002","unstructured":"Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, Jeong JH, Wolmark N (2002) Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347(16):1233\u20131241. https:\/\/doi.org\/10.1056\/NEJMoa022152","journal-title":"N Engl J Med"},{"issue":"5811","key":"1743_CR10","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1136\/bmj.2.5811.423","volume":"2","author":"H Atkins","year":"1972","unstructured":"Atkins H, Hayward JL, Klugman DJ, Wayte AB (1972) Treatment of early breast cancer: a report after ten years of a clinical trial. Br Med J 2(5811):423\u2013429. https:\/\/doi.org\/10.1136\/bmj.2.5811.423","journal-title":"Br Med J"},{"issue":"8","key":"1743_CR11","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1002\/1097-0142(19930415)71:8<2507::aid-cncr2820710813>3.0.co;2-0","volume":"71","author":"ER Fisher","year":"1993","unstructured":"Fisher ER, Anderson S, Redmond C, Fisher B (1993) Pathologic findings from the National Surgical Adjuvant Breast Project protocol B-06. 10-year pathologic and clinical prognostic discriminants. Cancer 71(8):2507\u20132514. https:\/\/doi.org\/10.1002\/1097-0142(19930415)71:8%3c2507::aid-cncr2820710813%3e3.0.co;2-0","journal-title":"Cancer"},{"issue":"8","key":"1743_CR12","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMoa020128","volume":"347","author":"B Fisher","year":"2002","unstructured":"Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N (2002) Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 347(8):567\u2013575. https:\/\/doi.org\/10.1056\/NEJMoa020128","journal-title":"N Engl J Med"},{"issue":"8174","key":"1743_CR13","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/s0140-6736(80)90856-9","volume":"1","author":"M Baum","year":"1980","unstructured":"Baum M, Houghton J (1980) Current and future management of \u201cearly\u201d breast cancer: attitude survey amongst participants in cancer research campaign trial. Lancet 1(8174):929. https:\/\/doi.org\/10.1016\/s0140-6736(80)90856-9","journal-title":"Lancet"},{"issue":"9804","key":"1743_CR14","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1016\/S0140-6736(11)61629-2","volume":"378","author":"S Darby","year":"2011","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group, Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M, Godwin J, Gray R, Pierce L, Whelan T, Wang Y, Peto R (2011) Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 378(9804):1707\u20131716. https:\/\/doi.org\/10.1016\/S0140-6736(11)61629-2","journal-title":"Lancet"},{"issue":"9935","key":"1743_CR15","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1016\/S0140-6736(14)60488-8","volume":"383","author":"MP Ebctcg","year":"2014","unstructured":"Ebctcg MP, Taylor C, Correa C, Cutter D, Duane F, Ewertz M, Gray R, Mannu G, Peto R, Whelan T, Wang Y, Wang Z, Darby S (2014) Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 383(9935):2127\u20132135. https:\/\/doi.org\/10.1016\/S0140-6736(14)60488-8","journal-title":"Lancet"},{"issue":"1","key":"1743_CR16","first-page":"7","volume":"71","author":"J Cuzick","year":"1987","unstructured":"Cuzick J, Stewart H, Peto R, Fisher B, Kaae S, Johansen H, Lythgoe JP, Prescott RJ (1987) Overview of randomized trials comparing radical mastectomy without radiotherapy against simple mastectomy with radiotherapy in breast cancer. Cancer Treat Rep 71(1):7\u201314","journal-title":"Cancer Treat Rep"},{"issue":"9814","key":"1743_CR17","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/S0140-6736(11)61625-5","volume":"379","author":"R Peto","year":"2012","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group, Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, Cutter D, Darby S, McGale P, Taylor C, Wang YC, Bergh J, Di Leo A, Albain K, Swain S, Piccart M, Pritchard K (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379(9814):432\u2013444. https:\/\/doi.org\/10.1016\/S0140-6736(11)61625-5","journal-title":"Lancet"},{"issue":"9935","key":"1743_CR18","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1016\/S0140-6736(14)60192-6","volume":"383","author":"P Poortmans","year":"2014","unstructured":"Poortmans P (2014) Postmastectomy radiation in breast cancer with one to three involved lymph nodes: ending the debate. Lancet 383(9935):2104\u20132106. https:\/\/doi.org\/10.1016\/S0140-6736(14)60192-6","journal-title":"Lancet"},{"issue":"1","key":"1743_CR19","first-page":"15","volume":"71","author":"J Cuzick","year":"1987","unstructured":"Cuzick J, Stewart H, Peto R, Baum M, Fisher B, Host H, Lythgoe JP, Ribeiro G, Scheurlen H, Wallgren A (1987) Overview of randomized trials of postoperative adjuvant radiotherapy in breast cancer. Cancer Treat Rep 71(1):15\u201329","journal-title":"Cancer Treat Rep"},{"issue":"6","key":"1743_CR20","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1002\/1097-0142(197706)39:6<2827::AID-CNCR2820390671>3.0.CO;2-I","volume":"39","author":"B Fisher","year":"1977","unstructured":"Fisher B, Montague E, Redmond C, Barton B, Borland D, Fisher ER, Deutsch M, Schwarz G, Margolese R, Donegan W, Volk H, Konvolinka C, Gardner B, Cohn I Jr, Lesnick G, Cruz AB, Lawrence W, Nealon T, Butcher H, Lawton R, Investigators ON (1977) Comparison of radical mastectomy with alternative treatments for primary breast cancer: a first report of results from a prospective randomized clinical trial. Cancer 39(6):2827\u20132839. https:\/\/doi.org\/10.1002\/1097-0142(197706)39:6%3c2827::AID-CNCR2820390671%3e3.0.CO;2-I","journal-title":"Cancer"},{"issue":"4","key":"1743_CR21","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/BF01806749","volume":"1","author":"N Wolmark","year":"1981","unstructured":"Wolmark N, Fisher B (1981) Surgery in the primary treatment of breast cancer. Breast Cancer Res Treat 1(4):339\u2013348. https:\/\/doi.org\/10.1007\/BF01806749","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"1743_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/1097-0142(19800701)46:1<1::aid-cncr2820460102>3.0.co;2-3","volume":"46","author":"B Fisher","year":"1980","unstructured":"Fisher B, Montague E, Redmond C, Deutsch M, Brown GR, Zauber A, Hanson WF, Wong A (1980) Findings from NSABP Protocol No. B-04-comparison of radical mastectomy with alternative treatments for primary breast cancer. I. Radiation compliance and its relation to treatment outcome. Cancer 46(1):1\u201313. https:\/\/doi.org\/10.1002\/1097-0142(19800701)46:1%3c1::aid-cncr2820460102%3e3.0.co;2-3","journal-title":"Cancer"},{"issue":"2","key":"1743_CR23","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.radonc.2018.03.013","volume":"127","author":"AN Abrunhosa-Branquinho","year":"2018","unstructured":"Abrunhosa-Branquinho AN, Bar-Deroma R, Collette S, Clementel E, Liu Y, Hurkmans CW, Feuvret L, Van Beek K, van den Bent M, Baumert BG, Weber DC (2018) Radiotherapy quality assurance for the RTOG 0834\/EORTC 26053-22054\/NCIC CTG CEC.1\/CATNON intergroup trial \u201cconcurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p\/19q deleted anaplastic glioma\u201d: Individual case review analysis. Radiother Oncol J Eur Soc Ther Radiol Oncol 127(2):292\u2013298. https:\/\/doi.org\/10.1016\/j.radonc.2018.03.013","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"issue":"18","key":"1743_CR24","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1200\/JCO.2009.27.4498","volume":"28","author":"LJ Peters","year":"2010","unstructured":"Peters LJ, O\u2019Sullivan B, Giralt J, Fitzgerald TJ, Trotti A, Bernier J, Bourhis J, Yuen K, Fisher R, Rischin D (2010) Critical Impact of Radiotherapy Protocol Compliance and Quality in the Treatment of Advanced Head and Neck Cancer: Results From TROG 02.02. J Clin Oncol 28(18):2996\u20133001. https:\/\/doi.org\/10.1200\/JCO.2009.27.4498","journal-title":"J Clin Oncol"},{"issue":"6","key":"1743_CR25","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1080\/02841860902824917","volume":"48","author":"S Friberg","year":"2009","unstructured":"Friberg S, Ruden BI (2009) Hypofractionation in radiotherapy. An investigation of injured Swedish women, treated for cancer of the breast. Acta Oncol 48(6):822\u2013831. https:\/\/doi.org\/10.1080\/02841860902824917","journal-title":"Acta Oncol"},{"key":"1743_CR26","doi-asserted-by":"crossref","unstructured":"Cancer research campaign (King's\/Cambridge) trial for early breast cancer. A detailed update at the tenth year. Cancer Research Campaign Working Party (1980). Lancet 2 (8185):55\u201360","DOI":"10.1016\/S0140-6736(80)92939-6"},{"issue":"676","key":"1743_CR27","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1259\/0007-1285-57-676-309","volume":"57","author":"D Brinkley","year":"1984","unstructured":"Brinkley D, Haybittle JL, Houghton J (1984) The Cancer Research Campaign (King\u2019s\/Cambridge) trial for early breast cancer: an analysis of the radiotherapy data. Br J Radiol 57(676):309\u2013316. https:\/\/doi.org\/10.1259\/0007-1285-57-676-309","journal-title":"Br J Radiol"},{"issue":"12","key":"1743_CR28","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1002\/bjs.1800691202","volume":"69","author":"JP Lythgoe","year":"1982","unstructured":"Lythgoe JP, Palmer MK (1982) Manchester regional breast study\u20135 and 10 year results. Br J Surg 69(12):693\u2013696. https:\/\/doi.org\/10.1002\/bjs.1800691202","journal-title":"Br J Surg"},{"issue":"1","key":"1743_CR29","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/0960-9776(94)90034-5","volume":"3","author":"HJ Stewart","year":"1994","unstructured":"Stewart HJ, Jack WJL, Everington D, Forrest APM, Rodger A, McDonald CC, Prescott RJ, Langlands AO (1994) South-east Scottish trial of local therapy in node negative breast cancer. The Breast 3(1):31\u201339. https:\/\/doi.org\/10.1016\/0960-9776(94)90034-5","journal-title":"The Breast"},{"issue":"2","key":"1743_CR30","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/s0167-8140(86)80090-1","volume":"7","author":"JW Denham","year":"1986","unstructured":"Denham JW (1986) The radiation dose-response relationship for control of primary breast cancer Radiotherapy and oncology. j Eur Soc Ther Radiol Oncol 7(2):107\u2013123. https:\/\/doi.org\/10.1016\/s0167-8140(86)80090-1","journal-title":"j Eur Soc Ther Radiol Oncol"},{"issue":"3","key":"1743_CR31","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/SLA.0000000000001863","volume":"264","author":"AE Giuliano","year":"2016","unstructured":"Giuliano AE, Ballman K, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, Saha S, Morrow M, Hunt KK (2016) Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: long-term follow-up from the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial. Ann Surg 264(3):413\u2013420. https:\/\/doi.org\/10.1097\/SLA.0000000000001863","journal-title":"Ann Surg"},{"issue":"10","key":"1743_CR32","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2017.11470","volume":"318","author":"AE Giuliano","year":"2017","unstructured":"Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, Ollila DW, Hansen NM, Whitworth PW, Blumencranz PW, Leitch AM, Saha S, Hunt KK, Morrow M (2017) Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA 318(10):918\u2013926. https:\/\/doi.org\/10.1001\/jama.2017.11470","journal-title":"JAMA"},{"key":"1743_CR33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01565","author":"SAL Bartels","year":"2022","unstructured":"Bartels SAL, Donker M, Poncet C, Sauv\u00e9 N, Straver ME, van de Velde CJH, Mansel RE, Blanken C, Orzalesi L, Klinkenbijl JHG, van der Mijle HCJ, Nieuwenhuijzen GAP, Veltkamp SC, van Dalen T, Marinelli A, Rijna H, Snoj M, Bundred NJ, Merkus JWS, Belkacemi Y, Petignat P, Schinagl DAX, Coens C, van Tienhoven G, van Duijnhoven F, Rutgers EJT (2022) Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer: 10-year results of the randomized controlled EORTC 10981\u201322023 AMAROS Trial. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.22.01565","journal-title":"J Clin Oncol"},{"issue":"3","key":"1743_CR34","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.radonc.2016.08.027","volume":"121","author":"JS Haviland","year":"2016","unstructured":"Haviland JS, Bentzen SM, Bliss JM, Yarnold JR (2016) Prolongation of overall treatment time as a cause of treatment failure in early breast cancer: an analysis of the UK START (Standardisation of Breast Radiotherapy) trials of radiotherapy fractionation Radiotherapy and oncology. j Eur Soc Ther Radiol Oncol 121(3):420\u2013423. https:\/\/doi.org\/10.1016\/j.radonc.2016.08.027","journal-title":"j Eur Soc Ther Radiol Oncol"},{"issue":"11","key":"1743_CR35","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/S1470-2045(13)70386-3","volume":"14","author":"JS Haviland","year":"2013","unstructured":"Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett J, Barrett-Lee PJ, Dobbs HJ, Hopwood P, Lawton PA, Magee BJ, Mills J, Simmons S, Sydenham MA, Venables K, Bliss JM, Yarnold JR, Group ST (2013) The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol 14(11):1086\u20131094. https:\/\/doi.org\/10.1016\/S1470-2045(13)70386-3","journal-title":"Lancet Oncol"},{"issue":"1","key":"1743_CR36","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/PPO.0000000000000496","volume":"27","author":"M Machiels","year":"2021","unstructured":"Machiels M, Kaidar-Person O, Rubio IT, Poortmans P (2021) Local treatment of triple-negative breast cancer. Cancer J 27(1):32\u201340. https:\/\/doi.org\/10.1097\/PPO.0000000000000496","journal-title":"Cancer J"},{"issue":"2","key":"1743_CR37","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.radonc.2011.01.010","volume":"100","author":"XS Qi","year":"2011","unstructured":"Qi XS, White J, Li XA (2011) Is \u03b1\/\u03b2 for breast cancer really low? Radiother Oncol J Eur Soc Ther Radiol Oncol 100(2):282\u2013288. https:\/\/doi.org\/10.1016\/j.radonc.2011.01.010","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"issue":"1","key":"1743_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijrobp.2010.08.035","volume":"79","author":"J Yarnold","year":"2011","unstructured":"Yarnold J, Bentzen SM, Coles C, Haviland J (2011) Hypofractionated whole-breast radiotherapy for women with early breast cancer: myths and realities. Int J Radiat Oncol Biol Phys 79(1):1\u20139. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.08.035","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1743_CR39","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.breast.2022.01.018","volume":"62","author":"GN Marta","year":"2022","unstructured":"Marta GN, Riera R, Pacheco RL, Cabrera Martimbianco AL, Meattini I, Kaidar-Person O, Poortmans P (2022) Moderately hypofractionated post-operative radiation therapy for breast cancer: systematic review and meta-analysis of randomized clinical trials. Breast 62:84\u201392. https:\/\/doi.org\/10.1016\/j.breast.2022.01.018","journal-title":"Breast"},{"key":"1743_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.904063","volume":"13","author":"X Lin","year":"2022","unstructured":"Lin X, Kong D, Chen ZS (2022) Editorial: chemo-radiation-resistance in cancer therapy. Front Pharmacol 13:904063. https:\/\/doi.org\/10.3389\/fphar.2022.904063","journal-title":"Front Pharmacol"},{"key":"1743_CR41","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ctro.2020.04.001","volume":"22","author":"M Ansems","year":"2020","unstructured":"Ansems M, Span PN (2020) The tumor microenvironment and radiotherapy response; a central role for cancer-associated fibroblasts. Clin Transl Radiation Oncol 22:90\u201397. https:\/\/doi.org\/10.1016\/j.ctro.2020.04.001","journal-title":"Clin Transl Radiation Oncol"},{"issue":"12","key":"1743_CR42","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s11912-019-0850-y","volume":"21","author":"\u00c1 Montero","year":"2019","unstructured":"Montero \u00c1, Ci\u00e9rvide R, Poortmans P (2019) When can we avoid postmastectomy radiation following primary systemic therapy? Curr Oncol Rep 21(12):95. https:\/\/doi.org\/10.1007\/s11912-019-0850-y","journal-title":"Curr Oncol Rep"},{"issue":"6","key":"1743_CR43","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1200\/JCO.2013.51.3523","volume":"32","author":"LB Marks","year":"2014","unstructured":"Marks LB, Prosnitz LR (2014) Reducing local therapy in patients responding to preoperative systemic therapy: are we outsmarting ourselves? J Clin Oncol Off J Am Soc Clin Oncol 32(6):491\u2013493. https:\/\/doi.org\/10.1200\/JCO.2013.51.3523","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"23","key":"1743_CR44","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.1200\/JCO.2004.11.129","volume":"22","author":"EH Huang","year":"2004","unstructured":"Huang EH, Tucker SL, Strom EA, McNeese MD, Kuerer HM, Buzdar AU, Valero V, Perkins GH, Schechter NR, Hunt KK, Sahin AA, Hortobagyi GN, Buchholz TA (2004) Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. J Clin Oncol Off J Am Soc Clin Oncol 22(23):4691\u20134699. https:\/\/doi.org\/10.1200\/JCO.2004.11.129","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"3","key":"1743_CR45","doi-asserted-by":"publisher","first-page":"505","DOI":"10.4161\/cc.8.3.7608","volume":"8","author":"U Del Monte","year":"2009","unstructured":"Del Monte U (2009) Does the cell number 10(9) still really fit one gram of tumor tissue? Cell Cycle 8(3):505\u2013506. https:\/\/doi.org\/10.4161\/cc.8.3.7608","journal-title":"Cell Cycle"},{"issue":"6","key":"1743_CR46","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s00259-005-0038-6","volume":"33","author":"BM Fischer","year":"2006","unstructured":"Fischer BM, Olsen MW, Ley CD, Klausen TL, Mortensen J, H\u00f8jgaard L, Kristjansen PE (2006) How few cancer cells can be detected by positron emission tomography? A frequent question addressed by an in vitro study. Eur J Nucl Med Mol Imaging 33(6):697\u2013702. https:\/\/doi.org\/10.1007\/s00259-005-0038-6","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"1743_CR47","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.radonc.2016.12.021","volume":"122","author":"O Gentilini","year":"2017","unstructured":"Gentilini O, Botteri E, Leonardi MC, Rotmensz N, Vila J, Peradze N, Thomazini MV, Jereczek BA, Galimberti V, Luini A, Veronesi P, Orecchia R (2017) Ipsilateral axillary recurrence after breast conservative surgery: The protective effect of whole breast radiotherapy. Radiother Oncol J Eur Soc Ther Radiol Oncol 122(1):37\u201344. https:\/\/doi.org\/10.1016\/j.radonc.2016.12.021","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"issue":"10099","key":"1743_CR48","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/S0140-6736(17)31145-5","volume":"390","author":"CE Coles","year":"2017","unstructured":"Coles CE, Griffin CL, Kirby AM, Titley J, Agrawal RK, Alhasso A, Bhattacharya IS, Brunt AM, Ciurlionis L, Chan C, Donovan EM, Emson MA, Harnett AN, Haviland JS, Hopwood P, Jefford ML, Kaggwa R, Sawyer EJ, Syndikus I, Tsang YM, Wheatley DA, Wilcox M, Yarnold JR, Bliss JM, Trialists I (2017) Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet 390(10099):1048\u20131060. https:\/\/doi.org\/10.1016\/S0140-6736(17)31145-5","journal-title":"Lancet"},{"issue":"4","key":"1743_CR49","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.ijrobp.2020.04.042","volume":"107","author":"G Hildebrandt","year":"2020","unstructured":"Hildebrandt G, Stachs A, Gerber B, Potenberg J, Krug D, Wolter K, Kuhn T, Zierhut D, Sedlmayer F, Kaiser J, Reitsamer R, Heil J, Nekljudova V, Bekes I, Loibl S, Reimer T (2020) Central review of radiation therapy planning among patients with breast-conserving surgery: results from a quality assurance process integrated into the INSEMA trial. Int J Radiat Oncol Biol Phys 107(4):683\u2013693. https:\/\/doi.org\/10.1016\/j.ijrobp.2020.04.042","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"518","key":"1743_CR50","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1259\/0007-1285-44-518-101","volume":"44","author":"F Ellis","year":"1971","unstructured":"Ellis F (1971) Nominal standard dose and the ret. Br J Radiol 44(518):101\u2013108. https:\/\/doi.org\/10.1259\/0007-1285-44-518-101","journal-title":"Br J Radiol"},{"issue":"991","key":"1743_CR51","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1259\/bjr\/31372149","volume":"83","author":"JF Fowler","year":"2010","unstructured":"Fowler JF (2010) 21 years of biologically effective dose. Br J Radiol 83(991):554\u2013568. https:\/\/doi.org\/10.1259\/bjr\/31372149","journal-title":"Br J Radiol"},{"issue":"28","key":"1743_CR52","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.1200\/JCO.19.02750","volume":"38","author":"AM Brunt","year":"2020","unstructured":"Brunt AM, Haviland JS, Sydenham M, Agrawal RK, Algurafi H, Alhasso A, Barrett-Lee P, Bliss P, Bloomfield D, Bowen J, Donovan E, Goodman A, Harnett A, Hogg M, Kumar S, Passant H, Quigley M, Sherwin L, Stewart A, Syndikus I, Tremlett J, Tsang Y, Venables K, Wheatley D, Bliss JM, Yarnold JR (2020) Ten-year results of FAST: a randomized controlled trial of 5-fraction whole-breast radiotherapy for early breast cancer. J Clin Oncol Off J Am Soc Clin Oncol 38(28):3261\u20133272. https:\/\/doi.org\/10.1200\/JCO.19.02750","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"10237","key":"1743_CR53","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1016\/S0140-6736(20)30932-6","volume":"395","author":"A Murray Brunt","year":"2020","unstructured":"Murray Brunt A, Haviland JS, Wheatley DA, Sydenham MA, Alhasso A, Bloomfield DJ, Chan C, Churn M, Cleator S, Coles CE, Goodman A, Harnett A, Hopwood P, Kirby AM, Kirwan CC, Morris C, Nabi Z, Sawyer E, Somaiah N, Stones L, Syndikus I, Bliss JM, Yarnold JR, Group FA-FTM (2020) Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet 395(10237):1613\u20131626. https:\/\/doi.org\/10.1016\/S0140-6736(20)30932-6","journal-title":"Lancet"},{"key":"1743_CR54","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.00655","author":"M Sj\u00f6str\u00f6m","year":"2023","unstructured":"Sj\u00f6str\u00f6m M, Fyles A, Liu FF, McCready D, Shi W, Rey-McIntyre K, Chang SL, Feng FY, Speers CW, Pierce LJ, Holmberg E, Fern\u00f6 M, Malmstr\u00f6m P, Karlsson P (2023) Development and validation of a genomic profile for the omission of local adjuvant radiation in breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. https:\/\/doi.org\/10.1200\/jco.22.00655","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"2","key":"1743_CR55","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/s1470-2045(16)30648-9","volume":"18","author":"JG Scott","year":"2017","unstructured":"Scott JG, Berglund A, Schell MJ, Mihaylov I, Fulp WJ, Yue B, Welsh E, Caudell JJ, Ahmed K, Strom TS, Mellon E, Venkat P, Johnstone P, Foekens J, Lee J, Moros E, Dalton WS, Eschrich SA, McLeod H, Harrison LB, Torres-Roca JF (2017) A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study. Lancet Oncol 18(2):202\u2013211. https:\/\/doi.org\/10.1016\/s1470-2045(16)30648-9","journal-title":"Lancet Oncol"},{"key":"1743_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14051246","author":"C Matuschek","year":"2022","unstructured":"Matuschek C, Jazmati D, B\u00f6lke E, Tamaskovics B, Corradini S, Budach W, Krug D, Mohrmann S, Ruckh\u00e4berle E, Fehm T, Nestle Kr\u00e4mling C, Dommach M, Haussmann J (2022) Post-neoadjuvant treatment strategies in breast cancer. Cancers. https:\/\/doi.org\/10.3390\/cancers14051246","journal-title":"Cancers"},{"issue":"9","key":"1743_CR57","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/S1470-2045(22)00482-X","volume":"23","author":"SR de Wild","year":"2022","unstructured":"de Wild SR, de Munck L, Simons JM, Verloop J, van Dalen T, Elkhuizen PHM, Houben RMA, van Leeuwen AE, Linn SC, Pijnappel RM, Poortmans PMP, Strobbe LJA, Wesseling J, Voogd AC, Boersma LJ (2022) De-escalation of radiotherapy after primary chemotherapy in cT1\u20132N1 breast cancer (RAPCHEM; BOOG 2010\u201303): 5-year follow-up results of a Dutch, prospective, registry study. Lancet Oncol 23(9):1201\u20131210. https:\/\/doi.org\/10.1016\/S1470-2045(22)00482-X","journal-title":"Lancet Oncol"},{"key":"1743_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12123698","author":"T Reimer","year":"2020","unstructured":"Reimer T, Glass A, Botteri E, Loibl S, Gentilini OD (2020) Avoiding axillary sentinel lymph node biopsy after neoadjuvant systemic therapy in breast cancer: rationale for the prospective, multicentric EUBREAST-01 trial. Cancers. https:\/\/doi.org\/10.3390\/cancers12123698","journal-title":"Cancers"},{"key":"1743_CR59","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.breast.2021.09.004","volume":"60","author":"WP Weber","year":"2021","unstructured":"Weber WP, Matrai Z, Hayoz S, Tausch C, Henke G, Zwahlen DR, Gruber G, Zimmermann F, Seiler S, Maddox C, Ruhstaller T, Muenst S, Ackerknecht M, Kuemmel S, Bjelic-Radisic V, Kurzeder C, \u00dajhelyi M, Vrieling C, Satler R, Meyer I, Becciolini C, Bucher S, Simonson C, Fehr PM, Gabriel N, Mar\u00e1z R, Sarlos D, Dedes KJ, Leo C, Berclaz G, Dubsky P, Exner R, Fansa H, Hager C, Reisenberger K, Singer CF, Reitsamer R, Reinisch M, Winkler J, Lam GT, Fehr MK, Naydina T, Kohlik M, Clerc K, Ostapenko V, Fitzal F, Nussbaumer R, Maggi N, Schulz A, Markellou P, Leli\u00e8vre L, Egle D, Heil J, Knauer M (2021) Tailored axillary surgery in patients with clinically node-positive breast cancer: pre-planned feasibility substudy of TAXIS (OPBC-03, SAKK 23\/16, IBCSG 57\u201318, ABCSG-53, GBG 101). Breast 60:98\u2013110. https:\/\/doi.org\/10.1016\/j.breast.2021.09.004","journal-title":"Breast"},{"issue":"1","key":"1743_CR60","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1186\/s13063-018-3021-9","volume":"19","author":"G Henke","year":"2018","unstructured":"Henke G, Knauer M, Ribi K, Hayoz S, G\u00e9rard MA, Ruhstaller T, Zwahlen DR, Muenst S, Ackerknecht M, Hawle H, Fitzal F, Gnant M, M\u00e1trai Z, Ballardini B, Gyr A, Kurzeder C, Weber WP (2018) Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial. Trials 19(1):667. https:\/\/doi.org\/10.1186\/s13063-018-3021-9","journal-title":"Trials"},{"issue":"10","key":"1743_CR61","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.1245\/s10434-014-3908-y","volume":"21","author":"P Whitworth","year":"2014","unstructured":"Whitworth P, Stork-Sloots L, de Snoo FA, Richards P, Rotkis M, Beatty J, Mislowsky A, Pellicane JV, Nguyen B, Lee L, Nash C, Gittleman M, Akbari S, Beitsch PD (2014) Chemosensitivity predicted by blueprint 80-gene functional subtype and mammaprint in the prospective neoadjuvant breast registry symphony trial (NBRST). Ann Surg Oncol 21(10):3261\u20133267. https:\/\/doi.org\/10.1245\/s10434-014-3908-y","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"1743_CR62","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1158\/1078-0432.CCR-15-0630","volume":"22","author":"A Prat","year":"2016","unstructured":"Prat A, Galv\u00e1n P, Jimenez B, Buckingham W, Jeiranian HA, Schaper C, Vidal M, \u00c1lvarez M, D\u00edaz S, Ellis C, Nuciforo P, Ferree S, Ribelles N, Adamo B, Ram\u00f3n y Cajal S, Peg V, Alba E (2016) Prediction of response to neoadjuvant chemotherapy using core needle biopsy samples with the prosigna assay. Clin Cancer Res 22(3):560\u2013566. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0630","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1743_CR63","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1245\/s10434-018-07107-8","volume":"26","author":"AM Pease","year":"2019","unstructured":"Pease AM, Riba LA, Gruner RA, Tung NM, James TA (2019) Oncotype DX(\u00ae) recurrence score as a predictor of response to neoadjuvant chemotherapy. Ann Surg Oncol 26(2):366\u2013371. https:\/\/doi.org\/10.1245\/s10434-018-07107-8","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"1743_CR64","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1200\/jco.20.00853","volume":"39","author":"R Buus","year":"2021","unstructured":"Buus R, Sestak I, Kronenwett R, Ferree S, Schnabel CA, Baehner FL, Mallon EA, Cuzick J, Dowsett M (2021) Molecular drivers of oncotype DX, prosigna, EndoPredict, and the breast cancer index: a TransATAC study. J Clin Oncol Off J Am Soc Clin Oncol 39(2):126\u2013135. https:\/\/doi.org\/10.1200\/jco.20.00853","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"1743_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103801","volume":"75","author":"A Prat","year":"2022","unstructured":"Prat A, Guarneri V, Pascual T, Bras\u00f3-Maristany F, Sanfeliu E, Par\u00e9 L, Schettini F, Mart\u00ednez D, Jares P, Griguolo G, Dieci MV, Cort\u00e9s J, Llombart-Cussac A, Conte B, Mar\u00edn-Aguilera M, Chic N, Puig-Butill\u00e9 JA, Mart\u00ednez A, Galv\u00e1n P, Tsai YH, Gonz\u00e1lez-Farr\u00e9 B, Mira A, Vivancos A, Villagrasa P, Parker JS, Conte P, Perou CM (2022) Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer. EBioMedicine 75:103801. https:\/\/doi.org\/10.1016\/j.ebiom.2021.103801","journal-title":"EBioMedicine"},{"issue":"3","key":"1743_CR66","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/s1470-2045(23)00051-7","volume":"24","author":"SM Tolaney","year":"2023","unstructured":"Tolaney SM, Tarantino P, Graham N, Tayob N, Par\u00e8 L, Villacampa G, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis MJ, Shapira I, Wolff AC, Carey LA, Barroso-Sousa R, Villagrasa P, DeMeo M, DiLullo M, Zanudo JGT, Weiss J, Wagle N, Partridge AH, Waks AG, Hudis CA, Krop IE, Burstein HJ, Prat A, Winer EP (2023) Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial. Lancet Oncol 24(3):273\u2013285. https:\/\/doi.org\/10.1016\/s1470-2045(23)00051-7","journal-title":"Lancet Oncol"},{"key":"1743_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104320","volume":"85","author":"V Guarneri","year":"2022","unstructured":"Guarneri V, Bras-Maristany F, Dieci MV, Griguolo G, Par L, Mar \u00cdn-Aguilera M, Miglietta F, Bottosso M, Giorgi CA, Blasco P, Castillo O, Galv NP, Vivancos A, Villagrasa P, Parker JS, Perou CM, Conte P, Prat A (2022) HER2DX genomic test in HER2-positive\/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: a correlative analysis from the PerELISA trial. EBioMedicine 85:104320. https:\/\/doi.org\/10.1016\/j.ebiom.2022.104320","journal-title":"EBioMedicine"}],"container-title":["La radiologia medica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11547-023-01743-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11547-023-01743-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11547-023-01743-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T13:14:31Z","timestamp":1708434871000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11547-023-01743-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,3]]},"references-count":67,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["1743"],"URL":"https:\/\/doi.org\/10.1007\/s11547-023-01743-1","relation":{},"ISSN":["1826-6983"],"issn-type":[{"value":"1826-6983","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,3]]},"assertion":[{"value":"18 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Trine Tramm \u2013 none related to the review, received fees for participating in advisory board and for giving lectures for Pfizer. Aleix Prat\u2014Dr. Prat, are equity stockholders of Reveal Genomics; Dr. Prat reports grants from Reveal Genomics, during the conduct of the study; other from Reveal Genomics, personal fees from Roche, grants and personal fees from AstraZeneca, grants and personal fees from Daiichi-Sankyo, grants and personal fees from Novartis, personal fees from Foundation Medicine, personal fees from Oncolytics Biotech, outside the submitted work; In addition, Dr. Prat has a patent HER2DX licensed to Reveal Genomics, and a patent WO 2018\/103834 licensed to Reveal Genomics. Icro Meattini\u2014declares occasional small fees received for advisory board supported by Eli Lilly, Novartis, Gilead, Seagen, Pfizer. The authors have no relevant financial or non-financial interests to disclose: OKP, TK, PHP, GO, PGM.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"As a review paper, the work does not need ethics approval, nor patient inform consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}